Eight years after an international workshop on myotonic dystrophy patient registries: case study of a global collaboration for a rare disease
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F18%3A10379278" target="_blank" >RIV/00216208:11130/18:10379278 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00216224:14110/18:00104212 RIV/65269705:_____/18:00069536 RIV/00064203:_____/18:10379278
Výsledek na webu
<a href="https://doi.org/10.1186/s13023-018-0889-0" target="_blank" >https://doi.org/10.1186/s13023-018-0889-0</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1186/s13023-018-0889-0" target="_blank" >10.1186/s13023-018-0889-0</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Eight years after an international workshop on myotonic dystrophy patient registries: case study of a global collaboration for a rare disease
Popis výsledku v původním jazyce
Background: Myotonic Dystrophy is the most common form of muscular dystrophy in adults, affecting an estimated 10 per 100,000 people. It is a multisystemic disorder affecting multiple generations with increasing severity. There are currently no licenced therapies to reverse, slow down or cure its symptoms. In 2009 TREAT-NMD (a global alliance with the mission of improving trial readiness for neuromuscular diseases) and the Marigold Foundation held a workshop of key opinion leaders to agree a minimal dataset for patient registries in myotonic dystrophy. Eight years after this workshop, we surveyed 22 registries collecting information on myotonic dystrophy patients to assess the proliferation and utility the dataset agreed in 2009. These registries represent over 10,000 myotonic dystrophy patients worldwide (Europe, North America, Asia and Oceania). Results: The registries use a variety of data collection methods (e.g. online patient surveys or clinician led) and have a variety of budgets (from being run by volunteers to annual budgets over (sic) 200,000). All registries collect at least some of the originally agreed data items, and a number of additional items have been suggested in particular items on cognitive impact. Conclusions: The community should consider how to maximise this collective resource in future therapeutic programmes.
Název v anglickém jazyce
Eight years after an international workshop on myotonic dystrophy patient registries: case study of a global collaboration for a rare disease
Popis výsledku anglicky
Background: Myotonic Dystrophy is the most common form of muscular dystrophy in adults, affecting an estimated 10 per 100,000 people. It is a multisystemic disorder affecting multiple generations with increasing severity. There are currently no licenced therapies to reverse, slow down or cure its symptoms. In 2009 TREAT-NMD (a global alliance with the mission of improving trial readiness for neuromuscular diseases) and the Marigold Foundation held a workshop of key opinion leaders to agree a minimal dataset for patient registries in myotonic dystrophy. Eight years after this workshop, we surveyed 22 registries collecting information on myotonic dystrophy patients to assess the proliferation and utility the dataset agreed in 2009. These registries represent over 10,000 myotonic dystrophy patients worldwide (Europe, North America, Asia and Oceania). Results: The registries use a variety of data collection methods (e.g. online patient surveys or clinician led) and have a variety of budgets (from being run by volunteers to annual budgets over (sic) 200,000). All registries collect at least some of the originally agreed data items, and a number of additional items have been suggested in particular items on cognitive impact. Conclusions: The community should consider how to maximise this collective resource in future therapeutic programmes.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30103 - Neurosciences (including psychophysiology)
Návaznosti výsledku
Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2018
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Orphanet Journal of Rare Diseases
ISSN
1750-1172
e-ISSN
—
Svazek periodika
13
Číslo periodika v rámci svazku
September
Stát vydavatele periodika
GB - Spojené království Velké Británie a Severního Irska
Počet stran výsledku
11
Strana od-do
—
Kód UT WoS článku
000443735900002
EID výsledku v databázi Scopus
2-s2.0-85053164564